Search API

PVax Publishing

PVax Editorial Standards

Our news team has fact-checked health news for over 20 years and is committed to publishing accurate information. We stand by the information we publish; if it's incorrect, we will change it as quickly as possible. Additionally, we take many steps to ensure accuracy, such as:

We investigate claims with skepticism, question assumptions, challenge conventional wisdom;

We confirm information with subject-matter experts and seek to corroborate what sources tell us by talking with other informed people or consulting documents;

We verify content, such as technical terms, stats, etc., against source documents or clarify who provides the information. For example, we may share relevant components of a story with a primary source or an outside expert to verify them.

We support these industry-leading non-profit health publishing criteria: EC's Code of Practice on Disinformation, Health News Review, and Retraction Watch.

PVax Publishing Goals

The World Health Organization has confirmed vaccine misinformation is a significant threat to global health that could reverse decades of progress in reducing disease. PVax's vaccine library integrates peer-reviewed information from the European Medicines Agency, the UK, India, China, Brazil, Australia, and other agencies. And we curate our content to enhance consumer understanding. Our editorial goal is to publish information adhering to the Plain Writing Act 2010.

Trustworthy - Only licensed providers edit our content, delivering 100% transparency.

Understandable— our clinical information is written in a positive voice and translated into a "main street" conversation.

Breaking research is contextually integrated into the news as it is published;

Experience - Each article is designed with uniform navigation, offering a consistent learning experience.

Editorial Independence

PV's digital newsroom is insulated from any interaction with advertisers. To avoid conflicts, we do not accept gifts or remuneration. Our news-gathering team is independent of commercial or political interests. Additionally, we do not allow third parties to "ghost-write" news articles. If you have any questions, contact [email protected].

The Medical Advisory Team works closely with pharmacists, doctors, and nurses across various specialty areas to ensure PrecisionVax's published content is accurate, actionable, and understandable. If you have any questions, please contact Dr. Robert Carlson at [email protected].

2 min read
Last Reviewed: 
Thursday, March 21, 2024 - 12:20
Description: 
Precision Vaccinations publishes fact-checked, provider review vaccine information.
TB vaccine

Are New Tuberculosis Vaccines Really Needed

M72/AS01E vaccine candidate has been in development since the early 2000
March 21, 2024
0 min read

A corporate venture firm focused on investing in companies developing innovative solutions and ideas today announced its participation in an extension of the Series C financing round for Nouscom, a clinical-stage immuno-oncology company.

Nouscom raised approximately $82 million in its oversubscribed Series C round, which was first announced in November 2023.

Angelini Ventures joins a syndicate of top-tier international healthcare investors by participating in Nouscom’s financing.

This new financing will enable Nouscom, based in Basel, Switzerland. to continue advancing and expanding its wholly-owned clinical pipeline to achieve multiple clinical value catalysts, including:

  • Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for treating Mismatch Repair/Microsatellite Instable Metastatic Colorectal Cancer.
  • Phase 1b study completion and progression of NOUS-209 monotherapy in Lynch Syndrome carriers investigating the potential to intercept, prevent, or delay cancer in high-risk individuals.
  • Completion of the Phase 1b study for NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs.

Dr. Marina Udier, Chief Executive Officer at Nouscom, commented in a press release on March 21, 2024: “We are delighted to have extended our successful Series C financing round and excited to have Angelini Ventures on board. Their support strengthens our commitment to innovation and accelerates our journey towards delivering next-generation treatments for cancer patients.”

Vaccine Treats: 
Cancer
Image: 
Image Caption: 
Nouscom website March 2024
Live Blog Update Author: 
Don Hackett
Location Tags: 
Rome
Include in VBT newsletter: 
0 min read

In 2023, the global Eliminate Yellow Fever Epidemics (EYE) secretariat led by the World Health Organization (WHO) coordinated preventive and responsive vaccination efforts.

As a result, about 62 million people in Africa received yellow fever vaccinations through EYE campaigns.

According to the WHO's Disease Outbreak News on March 20, 2024, a single yellow fever vaccination can provide lifelong protection and sustained immunity for around 90% of vaccinated individuals.

The WHO says yellow fever is an acute viral hemorrhagic disease. Cases can be difficult to distinguish from other viral hemorrhagic fevers such as arenavirus, hantavirus, or dengue. Related symptoms of yellow fever usually appear 3 to 6 days after the bite of an infected mosquito.

To notify international travelers, the U.S. Centers for Disease Control and Prevention advises against yellow fever vaccination when visiting countries with a low risk of virus exposure.

For Americans seeking protection from this mosquito-transmitted disease, the YF-VAX® vaccine is available at certified travel vaccine clinics and pharmacies in the U.S.

The CDC recently reported no locally acquired yellow fever cases in 2024.

Vaccine Treats: 
Yellow Fever
Image: 
Image Caption: 
IAMAT 2024
Live Blog Update Author: 
Don Hackett
Location Tags: 
Austin
Vaccine: 
YF-VAX Yellow Fever Vaccine
Include in VBT newsletter: 
0 min read

Millions of people's health is at risk by the mosquito-transmitted, vaccine-preventable chikungunya virus (CHIKV), but most Americans are unaware of its global impact.

In-person information about a newly approved chikungunya virus (CHIKV) vaccine will be shared at the Walter E. Washington Convention Center in Washington, D.C., from April 1-4, 2024.

Valneva SE, a France-based specialty vaccine company, today announced it will present its single-shot chikungunya vaccine for adults, IXCHIQ®, and participate in a panel discussion on efforts to eradicate chikungunya outbreaks at the 24th World Vaccine Congress.

XCHIQ®, the world's first and only chikungunya vaccine approved in the U.S., was recently recommended by the CDC's Advisory Committee on Immunization Practices for international travelers to at-risk areas.

As of March 21, 2024, CHIKV was identified in nearly 115 countries, primarily in the Region of the Americas. As of December 2023, approximately 460,000 CHIKV cases and 360 related deaths have been reported worldwide.

On the evening of April 2, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where the vaccine is a finalist for the Best Prophylactic Vaccine award for IXCHIQ®.

And on April 3, Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in the "Vaccine Development and Efforts towards Eradicating Chikungunya" panel discussion.

For further details, contact Laetitia Bachelot-Fontaine, VP, Global Communications and European Investor Relations, at [email protected]

Vaccine Treats: 
Chikungunya
Image: 
Image Caption: 
by Azael Pitti
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Saint-Herblain
Vaccine: 
IXCHIQ Chikungunya Vaccine Live
Include in VBT newsletter: 
yellow fever

Yellow Fever Outbreaks Cause 11% Case Fatality Rate

African Region Yellow Fever outbreaks March 2024
March 20, 2024
cholera vaccine 2024

Cholera Vaccine Shortage Puts Millions of Children At-Risk

International Coordinating Group on Vaccine Provision calls for urgent fast-tracking of cholera vaccine production
March 20, 2024
Europe

Vaccine Development Encouraged in Europe

Members of the European Parliament support comprehensive pharmaceutical policy reform
March 20, 2024
0 min read

Valneva SE today reported its consolidated financial results for the year ending December 31, 2023, and provided several key corporate updates. Valneva's commercial portfolio is composed of three travel vaccines, IXIARO®/JESPECT®, DUKORAL®, and IXCHIQ®.

Valneva raised its 2024 product sales guidance to between €160 million and €180 million due to an improved outlook regarding the IXIARO® supply constraints anticipated in February 2024.

The Company made excellent progress across the R&D pipeline with the U.S. FDA's approval of the single-shot chikungunya vaccine IXCHIQ®, the world's first and only vaccine to address this significant unmet medical need.

In today's press release, Peter Bühler, Valneva's Chief Financial Officer, commented, "In 2023, Valneva successfully executed key strategic objectives despite a difficult economic environment."

"Our chikungunya vaccine IXCHIQ® became the world's first licensed chikungunya vaccine available to address this significant unmet medical need, and we also managed to surpass our pre-pandemic product sales."

Valneva will host a live webcast of its full-year 2023 results conference call on March 20, 2024, at 3 p.m. CET/10 a.m. EDT. The webcast will also be available on the Company's website. Please refer to this link: https://edge.media-server.com/mmc/p/hom3riyt. 

Chikungunya is a viral disease transmitted by mosquitoes infected with the chikungunya virus. The World Health Organization says chikungunya outbreaks were identified in nearly 115 countries, primarily in the Region of the Americas, in 2023.

Vaccine Treats: 
Chikungunya
Image: 
Image Caption: 
ECDC chikungunya case map 2023
Live Blog Update Author: 
Don Hackett
Location Tags: 
Saint-Herblain
Vaccine: 
IXCHIQ Chikungunya Vaccine Live
Include in VBT newsletter: 
ACIP

Innovative Pneumococcal Conjugate Vaccine for Adults Approaches Approval

Merck V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development
March 19, 2024